Reuters logo
BRIEF-Merck says FDA to take extra 3 mos to review sugammadex anesthesia-reversal agent
March 15, 2013 / 1:46 PM / 5 years ago

BRIEF-Merck says FDA to take extra 3 mos to review sugammadex anesthesia-reversal agent

March 15 (Reuters) - Merck & Co Inc : * Says FDA will take extra 3 months to review sugammadex anesthesia-reversal

agent * Says now expects FDA review of marketing application to be completed in

second half 2013

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below